Dr. Sneed studies ways to improve treatment options for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), particularly those who are unable to participate in traditional clinical trials. His research also explores new pain relief methods for athletes suffering from nerve-related pain, using techniques like neurodynamic mobilization that offer alternatives when conventional rehabilitation fails. He aims to provide hope and new possibilities for patients facing difficult medical challenges.
Key findings
In a case study, Dr. Sneed's nerve mobilization method reduced a patient's pain from 8 to 2 on a pain scale, significantly improving their leg function.
In a clinical trial for patients with AML or MDS, a treatment combination led to a 35% response rate, thus giving new treatment options to those typically excluded from standard trials.
Another study showed that 79% of patients with AML or MDS survived at least 60 days after a combination treatment of azacitidine and vorinostat.
Dr. Sneed’s research on the drug ABT-737 demonstrated that its effectiveness against AML cells is affected by certain proteins, suggesting a need for targeted therapies to enhance treatment efficacy.
Frequently asked questions
Does Dr. Sneed study acute myeloid leukemia?
Yes, Dr. Sneed focuses on treatment options for patients with acute myeloid leukemia (AML), particularly those who are ineligible for standard clinical trials.
What treatments has Dr. Sneed researched?
He has researched a combination of drugs for AML and myelodysplastic syndromes and specialized techniques like nerve mobilization for pain relief.
Is Dr. Sneed's work relevant for patients with chronic pain?
Yes, Dr. Sneed's innovative approach to nerve mobilization offers significant relief to athletes and others suffering from chronic nerve-related pain.
What is neurodynamic mobilization?
Neurodynamic mobilization is a specialized technique aimed at relieving nerve-related pain through targeted movements and stretches.
Can patients with MDS benefit from Dr. Sneed's treatments?
Yes, Dr. Sneed’s research includes treatment options specifically designed for patients with myelodysplastic syndromes (MDS), providing hope for those who have limited choices.
Publications in plain English
Neurodynamic mobilization in a collegiate long jumper with exercise-induced lateral leg and ankle pain: A case report.
2018
Physiotherapy theory and practice
Cox T, Sneed T, Hamann H
Plain English This study looked at a 21-year-old college long jumper who had ankle and leg pain for seven months, which affected her ability to compete. After trying regular rehab without success, she found significant relief using a new method called nerve mobilization, which helped reduce her pain scores from 8 to 2 on a pain scale and improved her overall leg function. This approach is important because it shows that when traditional treatments fail, specialized nerve mobilization can provide a better solution for athletes with nerve-related pain.
Who this helps: This helps athletes suffering from chronic nerve pain.
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
2017
Leukemia
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G +23 more
Plain English Researchers studied whether patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), who are often excluded from clinical trials due to health concerns, could participate in a trial using a combination of two drugs: azacitidine and vorinostat. They found that 83% of these patients survived for at least 60 days after treatment, and when they expanded the study to include more patients, the overall 60-day survival rate was 79%, with an overall survival of about 7.6 months. This research shows that more patients who are typically left out of trials can be safely treated and may benefit from new therapies.
Who this helps: This helps patients with AML or MDS who often have other health issues.
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
2017
Leukemia
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G +23 more
Plain English This study focused on patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who couldn't participate in standard clinical trials. Researchers found that a specific treatment improved outcomes for these patients, leading to a response rate of about 35%. This finding is important because it offers hope and new options for individuals who usually have limited treatment choices.
Who this helps: This helps patients with AML and MDS who are ineligible for standard treatments.
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
2006
Cancer cell
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP +21 more
Plain English This study looked at how a drug called ABT-737 works against acute myeloid leukemia (AML) cells. Researchers found that while ABT-737 can kill these cancer cells, its effectiveness decreases when certain proteins, like phosphorylated BCL-2 or MCL-1, are present. By targeting these proteins, ABT-737 could potentially become a powerful treatment option for AML, as it doesn't harm normal blood cells.
Who this helps: This benefits patients with acute myeloid leukemia.